Similarly, Ding et al. demonstrated that CD133pos liver cancer cells were resistant to transforming growth factor β (TGF-β)-induced apoptosis and this effect could be blunted using a mitogen-activated protein kinase 1 (MEK1) inhibitor [109]. Here, MAP2K1 is linked to liver cancer.